Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 7/20 | 0.74 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | APP | P05067 | 1/20 | 0.57 |
| ▸ | CA12 | O43570 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
| ▸ | CA7 | P43166 | 1/20 | 0.57 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.57 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.57 |
| ▸ | CA9 | Q16790 | 1/20 | 0.57 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.57 |
| ▸ | MAOA | P21397 | 6/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methyl 2,4-Dihydroxybenzoate SCHEMBL5199862 | 0.96 | MAOB (0.68) | MAOBLMNAHPGDAPPCA12 | |
| SCHEMBL29717105 | 0.90 | MAOB (0.63) | MAOBLMNAHPGDAPPCA12 | |
| SCHEMBL710202 | 0.90 | MAOB (0.63) | MAOBLMNAHPGDAPPCA12 | |
| SCHEMBL7928394 | 0.88 | MAOB (0.59) | MAOBLMNAHPGDAPPCA12 | |
| SCHEMBL4212043 | 0.88 | MAOB (0.58) | MAOBHPGDAPPCA12CA1 | |
| SCHEMBL15615390 | 0.88 | MAOB (0.58) | MAOBLMNACA12CA1CA2 | |
| SCHEMBL3962253 | 0.88 | MAOB (0.61) | MAOBLMNAHPGDNPC1RAB9A | |
| SCHEMBL5336493 | 0.88 | MAOB (0.61) | MAOBLMNAHPGDAPPMAOA | |
| SCHEMBL29032428 | 0.88 | MAOB (0.58) | MAOBLMNAHPGDAPPCA12 | |
| SCHEMBL7901014 | 0.87 | MAOB (0.57) | MAOBLMNAHPGDCA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 177 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101795703-B | Peptide tyrosinase inhibitors and uses thereof | UNIV LELAND STANFORD JUNIOR | 2015-05-06 | — | — | CN | claimed |
| CN-103864892-A | Peptide tyrosinase inhibitors and uses thereof | UNIV LELAND STANFORD JUNIOR | 2014-06-18 | — | — | CN | claimed |
| US-8338364-B2 | Peptide tyrosinase inhibitors and uses thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2012-12-25 | — | — | US | claimed |
| US-20100330007-A1 | Imrpoved Skin Brightening Compositions | AMCOL INTERNATIONAL CORPORATION (US) | 2010-12-30 | — | — | US | claimed |
| EP-2247279-A1 | IMPROVED SKIN BRIGHTENING COMPOSITIONS | AMCOL INTERNATIONAL CORPORATION (US) | 2010-11-10 | — | — | EP | claimed |
| WO-2009099911-A1 | IMPROVED SKIN BRIGHTENING COMPOSITIONS | AMCOL INTERNATIONAL CORPORATION (US) | 2009-08-13 | — | — | WO | claimed |
| EP-4168399-B1 | COMPOUNDS AND THEIR USES AS MIF INHIBITORS | NANJING IMMUNOPHAGE BIOMEDICAL CO LTD (CN) | 2026-04-01 | — | — | EP | disclosed |
| US-20260053796-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS INC (US) | 2026-02-26 | — | — | US | disclosed |
| US-12427144-B2 | Compounds and methods for the targeted degradation of androgen receptor | ARVINAS OPERATIONS, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| CN-119039380-A | Oligopeptide with whitening activity, composition and application thereof | 欧诗漫生物股份有限公司 | 2024-11-29 | — | — | CN | disclosed |
| CN-119019490-A | Active oligopeptide, tandem protein, composition and application thereof | 欧诗漫生物股份有限公司 | 2024-11-26 | — | — | CN | disclosed |
| CN-119019489-A | Melanin inhibiting active oligopeptide, tandem protein, composition and application thereof | 欧诗漫生物股份有限公司 | 2024-11-26 | — | — | CN | disclosed |
| CN-119019309-A | GPR40 agonism-SSTR 5 antagonistic double-effect compound, preparation method and application thereof | 南昌大学 | 2024-11-26 | — | — | CN | disclosed |
| CN-1136556-A | Aromatic group substituted W-amino alkyl amide and alkyl amide | CIBA GEIGY CO LTD (CH) | 1996-11-27 | — | — | CN | disclosed |
| EP-0728128-A1 | SUBSTITUTED PHENYL COMPOUNDS | RHONE-POULENC RORER LIMITED (GB) | 1996-08-28 | — | — | EP | disclosed |
| WO-1996022775-A1 | TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1996-08-01 | — | — | WO | disclosed |
| EP-0714299-A4 | — | — | 1996-07-10 | — | — | EP | disclosed |
| EP-0714299-A1 | BENZOXAZINONE AND BENZOPYRIMIDINONE PIPERIDINYL TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | MERCK & CO. INC. (US) | 1996-06-05 | — | — | EP | disclosed |
| WO-1995013262-A1 | SUBSTITUTED PHENYL COMPOUNDS | RHONE-POULENC RORER LIMITED (GB) | 1995-05-18 | — | — | WO | disclosed |
| WO-1995002405-A1 | BENZOXAZINONE AND BENZOPYRIMIDINONE PIPERIDINYL TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1995-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260053796-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, NR5A1, KLK3 | MAOB 2609/4885LMNA 1536/4885HPGD 3321/4885 |
| US-12427144-B2 | Compounds and methods for the targeted degradation of androgen receptor | AR, KLK3, ACP3 | MAOB 1259/4885LMNA 3155/4885HPGD 542/4885 |
| US-20100330007-A1 | Imrpoved Skin Brightening Compositions | RARG, RBP4, RARA | MAOB 3477/4885LMNA 2524/4885HPGD 1899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.